Discontinued drugs 2011: Pulmonary, allergy, gastrointestinal and arthritis

Expert Opinion on Investigational Drugs

Volumn 21, Issue 11, 2012, Pages 1607-1618

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Asthma COPD allergy; Discontinued drugs; Psoriasis inflammation; Rheumatoid arthritis

Indexed keywords

ADL 5747; ADL 5859; ADX 415; AGG 523; ALMOREXANT; AMOLIMOGENE BEPIPLASMID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; AT 001; AZD 3199; AZD 9668; AZD 9819; CABOZANTINIB; CD 160; CP 75187; FEZAKINUMAB; FIGITUMUMAB; GAMMA INTERFERON; GLPG 0259; HLA DRB1 ANTIGEN; IL 094; ILV 095; INTERLEUKIN 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; JTS 653; MONOCLONAL ANTIBODY; OTELIXIZUMAB; PF 3635659; PF 4191834; PF 4494700; PF 4967544; PF 610355; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PMI 001; R 348; RG 7424; TIPELUKAST; TRIPTERYGIUM WILFORDII EXTRACT; TRX 1; TRX 385; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; XL 499; ZYK 101A;

ALZHEIMER DISEASE; ASTHMA; BIOLOGICAL THERAPY; BREAST CANCER; CHRONIC GRAFT REJECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETIC NEPHROPATHY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPLASIA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; LUNG CANCER; LUPUS ERYTHEMATOSUS; MULTIPLE SCLEROSIS; NEOPLASM; OVERACTIVE BLADDER; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN ANAPHYLAXIS; SLEEP DISORDER; SYSTEMIC SCLEROSIS; TRIPTERYGIUM WILFORDII; UPREGULATION; UTERUS MYOMA; VIRUS INFECTION;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION; LUNG DISEASES;

EID: 84867559382     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.712112     Document Type: Review

References (31)

1. Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999;11:219-25
2. Drees BE, Mills GB, Rommel C, Prestwich GD. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Expert Opin Ther Patents 2004; 14:703-32
3. Mattheakis L, Kearney P, Jaeger C, et al. Pi3kd: Discovery of potent and selective inhibitors. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Berlin; 2010
4. Pharmaprojects. 2011. Available from: http://www.pharmaprojects.com [Cited 2012]
5. TransTech P. Ttp-488
6. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004
7. Chang CC, Liu Z, Vlad G, et al. Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated t cells. J Immunol 2009;182:5208-16
8. Ng C, Stefanich E, Anand B, et al. Pharmacokinetics/pharmacodynamics of nondepleting anti-cd4 monoclonal antibody (trx1) in healthy human volunteers. Pharm Res 2006;23:95-103
9. McBride R. Exclusive: Tolerx cuts staff, auctioning assets after phiii failure. 2011.Available from: http://www.fiercebiotech.com/story/exclusive- tolerxcuts-staff-auctioning-assets-after-phiiifailure/2011-10-07
10. Newswire P. Phytomedics' novel oral disease modifying drug candidate pmi-001 demonstrates positive phase ii results in rheumatoid arthritis. Available from: http://www.prnewswire.com/newsreleases/phytomedics-novel-oral- diseasemodifying-drug-candidate-pmi-001-demonstrates-positive-phase-ii-results- inrheumatoid-arthritis-56534222.html
11. Witthuhn BA, Silvennoinen O, Miura O, et al. Involvement of the jak-3 janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994;370:153-7
12. Velotta JB, Deuse T, Haddad M, et al. A novel jak3 inhibitor, r348, attenuates chronic airway allograft rejection. Transplantation 2009;87:653-9
13. Available from: www.clinicaltrials.gov Study evaluating single dose of ilv-095 in psoriasis subjects. 2011.http://www.clinicaltrials.gov/ct2/show/ NCT01010542?term=ILV-095rank=1
14. Reuters T. Pfizer ends late-stage lungcancer study. 2009. Available from: http://www.reuters.com/article/2009/12/29/us-pfizeridUSTRE5BS3XY20091229
15. Watch C. Rheumatoid arthritis. 2011.Available from: http://www. centerwatch.com/clinical-trials/results/new-therapies/nmt-details.aspx? CatID=132
16. Hoever P, Dorffner G, Benes H, et al. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin Pharmacol Ther 2012;91:975-85
17. Steiner MA, Lecourt H, Strasser DS, et al. Differential effects of the dual orexin receptor antagonist almorexant and the gabaa-[alpha]1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 2011;36:848-56
18. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (adamts) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for c-terminal processing in vivo. Biochem J 2001;358:615-26
19. Struglics A, Larsson S, Pratta MA, et al. Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanaseand matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14:101-13
20. Adl5859 hcl. Available from: http://www.selleckchem.com/products/ADL- 5859.html
21. Medicinova. Diseases and products j mn-001 (bronchial asthma). Available from: http://www.medicinova.com/html/research-asthma.html
22. Medicinova. Diseases and products j mn-001 (intersitial cystitis). Available from: http://www.medicinova.com/html/research-interstitialcystitis. html
23. Rajasekaran M, Locke KW, Parsons CL. Mn-001, a novel oral anti-inflammatory agent, suppresses bladder hyperactivity in a rat model. BJU Int 2006;98:430-4
24. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2010;19:257-64
25. Prat M, Gavalda A, Fonquerna S, Miralpeix M. Inhaled muscarinic antagonists for respiratory diseases: a review of patents and current developments (2006-2010). Expert Opin Ther Patents 2011; 21:1543-73
26. Beeh K, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 2010;27:150-9
27. Masferrer JL, Zweifel BS, Hardy M, et al. Pharmacology of pf-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther 2010; 334:294-301
28. Glossop PA, Watson CAL, Price DA, et al. Inhalation by design: novel tertiary amine muscarinic m3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease. J Med Chem 2011;54:6888-904
29. Allvoices. Astellas to cease darexaban maleate development. 2011.Available from: http://www.allvoices.com/news/10475532-astellas-tocease- darexaban-maleate-development
30. Zeneca A. A phase i, single centre, double-blind, randomised, placebo-controlled, parallel-group, 2-part study to assess the safety, tolerability and pharmacokinetics of single and multiple ascending inhaled doses of azd9819 in healthy subjects. 2011. Available from: http://www. astrazenecaclinicaltrials. com/-mshost800325/content/clinical-trials/resources/ pdf/D3020C00001
31. Stevens T, Ekholm K, Granse M, et al. Azd9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase. J Pharmacol Exp Ther 2011;339:313-20